US Pharma MarketingAAIC26: The role of biomarkers in primary care and early diagnostics - Pharmaceutical Technology
Blood-based biomarkers could play a key role in detecting and treating Alzheimer’s early at the first point of contact, experts say. Blood-based biomarkers could play a key role in detecting and treating Alzheimer’s early at the first point of contact, experts say. Biomarkers could hold transformative potential in Alzheimer’s diagnosis, drug development, treatment and care, experts at AAIC 2026 say. Credit: vektorbird / Shutterstock.com. In recent years, there have been several core developments within the Alzheimer’s space – including the debut of the first disease-modifying therapies (DMTs), as well as the US regulatory clearance of the first blood-based Alzheimer’s diagnostic…
Blood-based biomarkers could play a key role in detecting and treating Alzheimer’s early at the first point of contact, experts say.
Source: Pharmaceutical Technology